Last reviewed · How we verify
SP plus amodiaquine
SP plus amodiaquine is a combination antimalarial medication that works by targeting the malaria parasite's life cycle.
SP plus amodiaquine is a combination antimalarial medication that works by targeting the malaria parasite's life cycle. Used for Treatment of uncomplicated malaria caused by Plasmodium falciparum, Prevention of malaria in areas with high transmission.
At a glance
| Generic name | SP plus amodiaquine |
|---|---|
| Also known as | Camoquin, Fansidar |
| Sponsor | London School of Hygiene and Tropical Medicine |
| Drug class | Antimalarial |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
The combination of SP (sulfadoxine and pyrimethamine) and amodiaquine is synergistic in its action against the malaria parasite. SP inhibits dihydropteroate synthase, an enzyme essential for the parasite's folate synthesis, while amodiaquine targets the parasite's DNA and interferes with its replication.
Approved indications
- Treatment of uncomplicated malaria caused by Plasmodium falciparum
- Prevention of malaria in areas with high transmission
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Headache
Key clinical trials
- Perennial Malaria Chemoprevention in the Malaria Vaccine Era (PHASE4)
- Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi (PHASE4)
- Parasite Clearance and Protection from Infection (PCPI) in Cameroon (PHASE3)
- Efficacy and Safety of Sulphadoxine-pyrimethamine and Amodiaquine in Ghanaian Pregnant Women (PHASE3)
- Evaluation of Vector and Chemoprevention-based Interventions to Reduce Malaria Burden in Urban Daaras of Touba, Senegal (PHASE4)
- Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Extension Study (PHASE3)
- Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE) (PHASE4)
- Seasonal Malaria Chemoprevention Rapid Assessment Study Mozambique (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SP plus amodiaquine CI brief — competitive landscape report
- SP plus amodiaquine updates RSS · CI watch RSS
- London School of Hygiene and Tropical Medicine portfolio CI